The University of Texas MD Anderson Cancer Center today announced the expansion of its global oncology efforts through a new agreement with the Ministry of Health of the Republic of Indonesia. This relationship builds on MD Anderson’s efforts to share best practices in cancer education, prevention, research and treatment to reduce the burden of cancer worldwide.
“It is vital for us to build relationships in countries where we can...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
The University of Texas MD Anderson Cancer Center and Federation Bio today announced a strategic collaboration to design and manufacture a...
Three researchers at The University of Texas MD Anderson Cancer Center have been named fellows of the American Association for the Advancement of Science (AAAS) for their notable contributions to the field of cancer research. This distinction is one of the highest honors in the scientific research community.
Stephen Lai, M.D., Ph.D., Cullen Taniguchi, M.D, Ph.D., and Apostolia Tsimberidou, M.D., Ph.D., now join this distinguished...
Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when...
The University of Texas MD Anderson Cancer Center today announced licensing agreements with BostonGene Corporation and Tempus for the MD Anderson...
Jennifer Wargo, M.D., professor of Surgical Oncology and Genomic Medicine at The University of Texas MD Anderson Cancer Center, has received...
A team of researchers led by The University of Texas MD Anderson Cancer Center has developed a novel delivery system for messenger RNA (mRNA...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved...